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Abstract
Introduction: Although prostatitis is a common male urinary tract infection, clinical diagnosis of prostatitis is difficult. The developmental mecha-
nism of prostatitis is not yet unraveled which led to the elaboration of various biomarkers. As changes in asparagine-linked-(N-)-glycosylation were 
observed between healthy volunteers (HV), patients with benign prostate hyperplasia and prostate cancer patients, a difference could exist in bio-
chemical parameters and urinary N-glycosylation between HV and prostatitis patients. We therefore investigated if prostatic protein glycosylation 
could improve the diagnosis of prostatitis.
Materials and methods: Differences in serum and urine biochemical markers and in total urine N-glycosylation profile of prostatic proteins were 
determined between HV (N = 66) and prostatitis patients (N = 36). Additionally, diagnostic accuracy of significant biochemical markers and changes 
in N-glycosylation was assessed.
Results: Urinary white blood cell (WBC) count enabled discrimination of HV from prostatitis patients (P < 0.001). Urinary bacteria count allowed for 
discriminating prostatitis patients from HV (P < 0.001). Total amount of biantennary structures (urinary 2A/MA marker) was significantly lower in 
prostatitis patients compared to HV (P < 0.001). Combining the urinary 2A/MA marker and urinary WBC count resulted in an AUC of 0.79, 95% con-
fidence interval (CI) = (0.70–0.89) which was significantly better than urinary WBC count (AUC = 0.70, 95% CI = [0.59–0.82], P = 0.042) as isolated 
test.
Conclusions: We have demonstrated the diagnostic value of urinary N-glycosylation profiling, which shows great potential as biomarker for prosta-
titis. Further research is required to unravel the developmental course of prostatic inflammation.
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Introduction
Prostatitis is a common male urinary tract infec-
tion with global prevalence ranging from 2.2% to 
9.7% (1). The term prostatitis describes a combina-
tion of infectious diseases which have been classi-
fied into 4 syndromes by the National Institutes of 
Health (2,3): acute bacterial prostatitis, chronic 
bacterial prostatitis, chronic non-bacterial prosta-
titis (inflammatory and non-inflammatory chronic 
pelvic pain syndrome), and, asymptomatic inflam-
matory prostatitis.
Clinical presentation of prostatitis is heterogene-
ous as it is based on patients symptoms, mainly 
pain at various locations and different degrees of 
lower urinary tract symptoms (LUTS, e.g. pain at 
the lower urinary tract, pain in the lower abdo-
men, pain at the perineal region, difficult voiding, 
frequent need to void, pain on urination or pain 
that increases with urination), and on presence of 
leukocyturia and bacteriuria (3,4). The diagnosis 
may however be difficult due to several reasons: 
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non-specific symptoms can arise (3), bacteria are 
only detected in 5 to 10% of cases (3,5), and an-
other underlying pathology, e.g. benign prostate 
hyperplasia (BPH), prostate cancer (PCa) and blad-
der carcinoma, could be present (3,6).
As the developmental mechanism of prostatitis is 
still unraveled, other inflammatory markers, such 
as interleukin-1β and tumor necrosis factor-α (7), 
and non-classic biomarkers, namely serum creati-
nine, urinary α1-microglobulin / creatinine ratio, 
urinary α2-macroglobulin/creatinine ratio and uri-
nary α2-macroglobulin / albumin ratio (8,9), have 
been examined for their potential use in prostatitis 
diagnosis. Currently, none of these parameters 
have been implemented in clinical routine labora-
tories.
Glycosylation studies have pointed out that infec-
tion and/or inflammation may alter the glycosyla-
tion patterns of host proteins. Two major hypoth-
eses on the mechanisms of these glycosylation al-
terations are: changes in metabolic activity, thus 
altering the availability of the carbohydrate donor 
molecules needed for the formation of complex 
asparagine-linked (N-) glycan structures by the 
Golgi enzymes; and/or; increased and rapid prolif-
eration during an immune response which over-
comes the limits of the glycosylation pathway, re-
stricting the relative amount of modification and 
complexity (10).
We have recently developed a technique to deter-
mine the N-glycosylation profile of urinary pros-
tate proteins (11). By means of this technique, we 
have proven that differences in N-glycans enabled 
distinction between BPH and PCa and that N-gly-
cosylation profiling could have an added value to 
PCa diagnosis, especially in the diagnostic gray 
zone of serum prostate specific antigen (sPSA) 
concentrations between 4 and 10 µg/L (12).
Because changes in N-glycosylation were ob-
served between healthy volunteers (HV), patients 
with BPH and PCa patients (12), we hypothesized 
that a difference could exist in biochemical param-
eters and urinary N-glycosylation between HV and 
prostatitis patients. As the use of N-glycomics has 
never been tested in prostatic inflammation, our 
objective in this diagnostic accuracy study is to de-
termine whether changes in N-glycosylation pat-
terns can differentiate between healthy volunteers 
(HV) and prostatitis patients and if these differenc-
es can improve prostatitis diagnosis.
Materials and methods
Subjects
From July 2012 to May 2015, a cohort of 36 prosta-
titis patients presenting at the Department of 
Urology at the Ghent University Hospital were 
continuously recruited and prospectively analyzed 
in our diagnostic accuracy study. Inclusion/exclu-
sion criteria consisted of: patients with at least one 
of the following symptoms of prostatitis: pain at 
the lower urinary tract, pain in the lower abdo-
men, pain at the perineal region, difficult voiding, 
frequent need to void, pain on urination or pain 
that increases with urination; but did not suffer 
from PCa. Acute or chronic bacterial prostatitis 
was confirmed on urinalysis: urinary white blood 
cell (WBC) count > 25 cells/µL and/or urinary bac-
teria count > 11.4 bacteria/µL (reference test). sPSA 
concentration was not used as inclusion criteria for 
prostatitis patients. Patients were included within 
6 weeks of onset of symptoms at which time a dig-
ital rectal examination (DRE) was performed (no 
DRE was performed at time of onset in order to 
prevent urosepsis (3)). Prostatitis patients consist-
ed of 16 acute bacterial prostatitis patients (of 
which 8 received antibiotic treatment); 9 chronic 
bacterial prostatitis patients (of which 4 received 
antibiotic treatment); and 11 chronic non-bacterial 
prostatitis patients (non-inflammatory chronic pel-
vic pain syndrome).
Healthy volunteers (N = 66) were enrolled as a ref-
erence group for comparison with the patient co-
hort and consisted of personnel from the Ghent 
University Hospital and family members of pa-
tients presenting at the Department of Urology at 
the Ghent University Hospital. Criteria used to en-
roll HV were: aged between 18 and 50 years, not 
suffering from any prostate pathology (BPH / PCa / 
LUTS or history of LUTS) and no first- or second-
line family member (father or brother) with PCa di-
agnosed before the age of 65.
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Informed consent was given by all participants 
and the study was approved by the local Ethics 
Committee (Belgian registration number: 
B670201214356). 
Methods
One Venosafe® VF-106SAS plastic serum silicone 
coated gel tube (Terumo Medical Corporation; 
Somerset, NJ, USA) was collected before DRE. The 
blood sample was allowed to coagulate during 30 
min and centrifuged at 3000 RPM for 10 minutes. 
The samples were analyzed for sPSA within 1 hour 
following sampling. Urine samples were collected 
directly after DRE in 60 mL urine containers (Inter-
national Medical Products n.v.; Brussels, Belgium). 
A 5 mL portion was transferred to 5 mL ultraclear 
polypropylene storage tubes (Deltalab, S.L.; Barce-
lona, Spain) and centrifuged at 3000 RPM for 10 
minutes. The centrifuged urine was aliquoted into 
2 portions: 3 mL was transferred to 5 mL ultraclear 
polypropylene storage tubes for urinary biochem-
ical analysis and 500 µL was transferred to 1.5 mL 
Eppendorf® Safe-Lock microcentrifuge tubes (No-
volab NV; Geraardsbergen, Belgium) for N-glyco-
sylation analysis. Aliquot for urine N-glycosylation 
analysis was preserved at -20 °C until assayed 
(within 1 week after preservation of the urine sam-
ples).
We used Cobas® 8000 modular P analyzer series 
(Roche Diagnostics GmbH, Mannheim, Germany) 
to measure total urinary protein concentrations 
and gamma-glutamyltranspeptidase (GGT) activi-
ty in urine. Total urinary protein was assayed by 
means of a robust pyrogallol-based dye binding 
method (13) using the Total Protein Reagent Pyro-
gallol Red Method with SDS reagent standardized 
according to Total Protein Standard Concentration 
1000 mg/L (within run coefficient of variation (CV) 
= 2.1%, between run CV = 2.1%). Upper reference 
values limit is taken at 0.2 g/L. All reagents and 
controls are commercially available (Instruchemie 
BV, Delfzijl, The Netherlands).
Urinary GGT activity was assessed to determine 
the presence of acute kidney injury (14,15). This as-
say was performed to determine the possible in-
fluence of highly glycosylated liver proteins on the 
urine N-glycosylation profile. Urinary GGT activity 
was measured through kinetic photometric deter-
mination (16) using the commercially available 
GGT-2 kit (Roche Diagnostics GmbH, Mannheim, 
Germany) with within run CV = 1.1% and between 
run CV = 1.3%. Normal male values range between 
12 and 64 U/L.
Immunonephelometry on a BN Nephelometer II 
analyzer (Siemens Healthcare, Marburg, Germany) 
was used to determine the albumin concentration 
in urine using commercially available N Antiserum 
to human albumin with N Protein standard SL as 
control (within run CV = 2.2%, between run CV = 
8.9%). Reference values range from 0 to 20 mg/L. 
All reagents and controls are commercially availa-
ble (Siemens Healthcare, Marburg, Germany).
sPSA, urinary total PSA (tPSA) and urinary free PSA 
(fPSA) were assayed by means of electrochemilu-
minescence immunoassay on a Modular E170 ana-
lyzer series (Roche Diagnostics GmbH, Mannheim, 
Germany) and standardized against the PreciCon-
trol Tumor marker 1 and 2. sPSA and urinary tPSA 
were assessed by means of the total PSA kit (with-
in run CV for PreciControl Tumor marker 1 and 2 = 
1.9% and = 0.8%, respectively; between run CV = 
4.2% and = 4.6%, respectively). Urinary fPSA was 
determined using the free PSA kit (within run CV 
for PreciControl Tumor marker 1 and 2 = 1.9% and 
= 0.8%, respectively; between run CV =2.0% and = 
1.9%, respectively). All reagents and controls are 
commercially available (Roche Diagnostics GmbH, 
Mannheim, Germany).
Urinary red blood cell (RBC) count (/µL), urinary 
white blood cell (WBC) count (/µL) and urinary 
bacteria count (/µL) were determined using a Sys-
mex UF-1000i® urinary flow cytometer (Sysmex 
Corporation, Kobe, Japan). The system uses a sem-
iconductor laser instrument to perform automat-
ed microscopic analysis and to automatically de-
tect, identify and count RBCs, WBCs and bacteria 
(17,18) with UF-Control as quality control (within 
run CV =2.2%, = 6.6% and = 9.2%, respectively; be-
tween run CV = 3.0%, = 2.0%, and = 3.0%, respec-
tively). All reagents and controls used are commer-
cially available (Sysmex Corporation, Kobe, Japan). 
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Upper reference limits implemented are 25 RBC/
µL, 25 WBC/µL and 11.4 bacteria/µL.
As previously described, urinary prostate protein 
N-glycans were determined using a multicapillary 
electrophoresis-based ABI3130 sequencer. Urinary 
prostate protein N-glycans were released using an 
on-membrane deglycosylation method and la-
beled with 8-aminopyrene-1,3,6-trisulphonic acid 
(Molecular Probes, Eugene, OR,USA). Subsequent-
ly, the glycans were desialylated overnight at 37 °C 
by the addition of 2 µL of 10 mM ammonium ace-
tate pH 5.0 containing 40 mU of Arthrobacter urea-
faciens α-2,3/6/8-sialidase (provided by the labora-
tory of Prof. Nico Callewaert, Unit for Medical Bio-
technology, Inflammation Research Center, VIB—
Ghent University, Ghent, Belgium). The desialylat-
ed N-glycan samples and a reference maltooligo-
saccharide ladder (dextran from Leuconostoc mes-
enteroides, Sigma-Aldrich, St. Louis, MO, USA) were 
analyzed with a multicapillary electrophoresis-
based ABI3130 sequencer. The peaks were ana-
lyzed with GeneMapper version 3.7 software (Ap-
plied Biosystems, Foster City, CA, USA) and peak 
height intensities were normalized to the total in-
tensity of the measured peaks (11). The method 
showed analytical variability of less than 5%. The 
difference in total amount of biantennary struc-
tures / multiantennary structures was named the 
‘urinary 2A/MA marker’, the difference in total 
amount of triantennary structures / multianten-
nary structures was named the ‘urinary 3A/MA 
marker’, and, the difference in total amount of 
tetraantennary structures / multiantennary struc-
tures was named the ‘urinary 4A/MA marker’. The 
different markers used for distinction of prostatitis 
patients from HV are given in Figure 1.
Statistical analysis
All participants were eligible for statistical analysis. 
Normal distribution of the subject groups was ver-
ified by D’Agostino-Pearson test. Overall differenc-
es between HV and prostatitis patients were ana-
lyzed by means of unpaired Student’s t-test (for 
normally distributed groups), Mann-Whitney U-
test (for non-normally distributed groups), or Fis-
cher exact test for categorical data. Receiver oper-
ating characteristic (ROC) curve analysis was used 
to determine criterion value of the urinary 2A/MA 
marker (index test) and to calculate area under the 
curve (AUC), sensitivity and specificity of the mark-
er with their respective 95% confidence interval 
(CI). Further analysis compared the ROC curve of 
the urinary 2A/MA marker with that of urinary 
WBC count (criterion ≥ 25 cells/µL) and urinary 
bacteria count (criterion ≥ 11.4 bacteria/µL). Crite-
rion values for urinary WBC count and urinary bac-
teria count were based on reference values cur-
rently used in our laboratory. Post-hoc calculation 
of criterion values was used to compare sensitivity 
Figure 1. Desialylated urinary N-glycan profiles of prostatic 
proteins from HV and prostatitis patients. X-axis depicts elu-
tion time; Y-axis represents relative fluorescence units. On top, 
a maltooligosaccharide ladder (dextran) is shown to determine 
the amount of structural units in each glycan structure. Identi-
fied glycosylation structures shown in the figure. Glycan sym-
bols are those suggested by the Consortium for Functional Gly-
comics (http://glycomics.scripps.edu/CFGnomenclature.pdf). 
Man6 stands for a mannose-rich structure that consists of 6 
mannose and 2 N-acetylglucosamine units. The concept of the 
figure was adapted from previously reported N-glycan profiles 
determined by means of the same technique (11). An increase 
was observed in the urinary 2A/MA marker (ratio [peaks D+E+F] 
/ [peaks D till J]) of prostatitis patients compared to HV (green 
arrows) while the urinary 3A/MA marker (ratio [peaks G+H] 
/ [peaks D till J]), and, the urinary 4A/MA marker (ratio [peaks 
I+J] / [peaks D till J]) were decreased in prostatitis patients com-
pared to HV (red arrows).
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and specificity of the post-hoc calculated criterion 
with those of the reference criterion currently 
used. Multivariate logistic regression was per-
formed to assess the additive diagnostic value of 
the urinary 2A/MA marker next to urinary WBC 
and bacteria count, and to calculate odds ratio 
(OR). Next, all prostatis patients were subdivided 
into acute versus chronic prostatis patients and 
into bacterial versus non-bacterial prostatis pa-
tients in order to assess differences in biochemical 
markers and N-glycans between these subgroups. 
P-values < 0.050 were considered statistically sig-
nificant. Statistical analyses were performed with 
MedCalc Statistical Software version 13.3.1.0 (Med-
Calc Software, Ostend, Belgium) and GraphPad 
Prism version 4.7 (GraphPad Software Inc., La Jolla, 
CA, USA).
Results
Baseline characteristics
The subjects’ baseline characteristics are summa-
rized in Table 1. Overall median sPSA concentra-
tion was significantly higher in prostatitis patients 
compared to HV (P < 0.001; Figure 2A), as was the 
urinary albumin concentration (P < 0.001; Figure 
2B). Next, urinary WBC count and urinary bacteria 
count was higher in prostatitis patients compared 
to HV (both P < 0.001; Figure 2C-D). Furthermore, 
urinary WBC count was significantly different 
when comparing acute versus chronic prostatitis (P 
= 0.029; Figure 2E) and in the comparison between 
bacterial versus non-bacterial prostatitis (P < 0.001; 
Figure 2F) whereas urinary bacteria count differed 
Characteristics Prostatitis patients HV P-value
Participants (%) 36 (35) 66 (65) N/A
Age (years) 55 (45–63) 29 (24–38) < 0 .001
sPSA (µg/L) 4.1 (1.2–7.6) 0.7 (0.5–1.0) < 0.001
Total urinary protein (g/L) 0.09 (0.03–0.17) 0.06 (0.03–0.10) 0.056
Urinary albumin (mg/L) 15.9 (7.2–38.3) 5.8 (3.2–12.4) < 0 .001
Ratio urinary albumin / total protein (%) 25 (12–37) 13 (8–26) 0.014
Urinary GGT activity (U/L) 28 (11–46) 16 (5–45) 0.216
Urinary total PSA (tPSA) (µg/L) 548 (180–2145) 340 (74–1417) 0.186
Ratio urinary tPSA / total protein (%) 0.9 (0.2–2.9) 0.6 (0.1–2.9) 0.839
Urinary free PSA (fPSA) (µg/L) 512 (153–1893) 278 (62–1114) 0.266
Ratio urinary fPSA / tPSA (%) 83 (74–89) 87 (79–92) 0.115
pH 6.5 (5.3–7.0) 6.5 (6.0–7.0) 0.980
Urinary RBC count (/µL) 7.9 (4.1–13.5) 5.6 (2.9–9.4) 0.124
Urinary WBC count (/µL) 21.8 (5.2–47.0) 5.9 (2.7–12.5) < 0 .001
Participants with urinary WBC count > 25.0 cells/µL (%) *† 17 (47) 10 (15) < 0 .001
Urinary bacteria count (/µL) 8.7 (2.8–30.5) 3.3 (1.8–5.6) < 0 .001
Participants with urinary bacteria count > 11.4 cells/µL *† 17 (47) 3 (5) < 0 .001
Data are median (interquartile range) except for participants: N (%). 
P-values are given for all parameters (Mann Whitney U-test). 
*Categorical data were assessed using Fisher Exact test; †percentages are given for group.
sPSA - serum prostate specific antigen; GGT - gamma-glutamyl transpeptidase; tPSA - total PSA; fPSA – free PSA; RBC - red blood 
cell; WBC - white blood cell; N/A - not applicable.
Table 1. Baseline characteristics of the population enrolled in the study.
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Figure 2. Differences in biochemical parameters between HV (N = 66) and prostatitis patients (N = 36). X-axis indicates the patient 
cohorts; Y-axis shows different biochemical parameters. Comparisons are illustrated for A: sPSA concentration (µg/L), B: urinary al-
bumin concentration (mg/L), C: overall urinary WBC count(/µL), D: overall urinary bacteria count (/µL) , E: urinary WBC count (/µL) in 
acute versus chronic prostatitis , F: urinary WBC count (/µL) in bacterial versus non bacterial prostatitis, G: urinary bacteria count (/µL) 
in acute versus chronic prostatitis , H: urinary bacteria count (/µL) in bacterial versus non bacterial prostatitis. Significance is depicted 
in the plots: P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***).
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only between bacterial and non-bacterial prostati-
tis (P = 0.002; Figure 2H) and was not significant 
between acute versus chronic prostatitis (P = 0.610; 
Figure 2G). None of the other biochemical markers 
was significantly different between prostatitis pa-
tients and HV (P > 0.050).
Changes in glycosylation patterns
All obtained N-glycan structures were examined. 
Normalization and analysis of the relative peak 
heights showed a difference between the N-gly-
can profiles of HV and prostatitis patients (Figure 
1). A significant increase of the urinary 2A/MA 
marker was found in the N-glycan profile of pros-
tatitis patients compared to HV (P < 0.001; Figure 
3A), which was the direct result of a decrease of 
the urinary 3A/MA and 4A/MA marker in prostati-
tis patients (P = 0.008 and P < 0.001, respectively; 
Figure 3B-C). No difference was observed in the 
percentage of overall core-α-1,6-fucosylation (P = 
0.051; Figure 3D). Also, no differences in N-glyco-
sylation were found between all types of prostati-
tis or between bacterial and non-bacterial prosta-
titis (P > 0.050).
Diagnostic accuracy of urinary WBC count, 
urinary bacteria count and the urinary 2A/MA 
marker in differentiating HV from prostatitis 
patients
The urinary 2A/MA marker showed fair diagnostic 
accuracy (AUC = 0.73, 95% CI [0.63-0.81], compara-
ble to urinary WBC count (AUC = 0.70, 95% CI 
[0.59-0.82]) and urinary bacteria count (AUC = 0.70, 
95% CI [0.58-0.82]; Figure 4). These tests did not 
differ significantly from each other (P = 0.508 and 
P = 0.586, respectively). Table 2 summarizes the 
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Significance is depicted in the plots: P < 0.01 (**) or P < 0.001 (***).
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discriminative power with matching sensitivity 
and specificity for these parameters in discriminat-
ing HV from prostatitis patients. Use of reference 
criterion values for urinary WBC count and urinary 
bacteria count resulted in a higher specificity while 
the use of the post-hoc calculated criterion value 
gave a higher sensitivity. Next, using multivariate 
logistic regression, urinary WBC and bacteria 
count were combined with the urinary 2A/MA 
marker (Table 2) which favored the combination of 
urinary WBC count and the urinary 2A/MA marker 
(urinary bacteria count was not included in the 
model). This combination of tests achieved fair di-
agnostic accuracy (AUC = 0.79, 95% CI [0.70-0.89]) 
which was significantly better compared to uri-
nary WBC as isolated test (P = 0.042) but not to uri-
nary bacteria count (P = 0.156; Figure 4).
Discussion
In our research, we assessed if differences existed 
between the urinary N-glycosylation profile of HV 
compared to prostatitis patients and if these dif-
ferences could assist in the diagnosis of prostatitis. 
Here we reported that changes in several serum 
and urinary biochemical markers occurred when 
Parameter Criterion Sensitivity (95% CI)
Specificity (95% 
CI) AUC (95% CI)
Logistic regression
OR (95% CI) P
Urinary WBC count > 14.6 /µL † 0.64(0.46–0.79)
0.80
(0.69–0.89) 0.70
(0.59–0.82)
1.02
(1.01–1.03) 0 .017
Urinary WBC count > 25.0 /µL * 0.44(0.28–0.62)
0.85
(0.74–0.92)
Urinary bacteria count > 6.5 /µL † 0.64(0.46–0.79)
0.85
(0.74–0.92) 0.70
(0.58–0.82)
1.00
(0.99–1.01) 0.078
Urinary bacteria count > 11.4 /µL * 0.47(0.30–0.65)
0.95
(0.87–0.99)
Urinary 2A/MA marker ≤ 0.588 † 0.75(0.58–0.88)
0.60
(0.47–0.72)
0.73
(0.63–0.81)
2.0 x 104
(62.9–6.5 x 106) <0 .001
Combining urinary WBC count and urinary 2A/MA marker resulted in an AUC of 0.79, 95% CI (0.70–0.87) with sensitivity = 0.69, 95% 
CI (0.52–0.84) and specificity = 0.78, 95% CI (0.67–0.88).
*Criterion values based on references values applied in our laboratory.; †criterion values calculated post-hoc. 
WBC - white blood cell; N/A - not applicable.
Table 2. Comparison of the discriminative power of several parameters for HV versus prostatitis patients and multivariate logistic 
regression model.
1 - Specicity
0.0
0.0
0.5
0.5
1.0
1.0
Se
ns
iti
vi
ty
Urinary bacteria count
Urinary WBC count
Urinary 2A/MA marker
Combination urinary WBC
count and 2A/MA marker
Figure 4. ROC curves analysis for the detection of prostatitis 
compared to HV. Analysis demonstrated AUC of 0.70, 95% CI 
[0.58-0.82]; 0.70, 95% CI [0.59-0.82]; and 0.73, 95% CI [0.63-0.81]; 
for urinary bacteria count (dashed line), urinary WBC count (thin 
full line) and the urinary 2A/MA marker (dotted line), respec-
tively. No significant differences were observed between the 
isolated tests (P > 0.050). Combining urinary WBC count and the 
urinary 2A/MA marker (bold full line) resulted in an AUC of 0.79, 
95% CI [0.70-0.89]; which was significantly better compared to 
urinary WBC count (P = 0.042) as isolated test but not to urinary 
bacteria count (P = 0.156). Diagonal segments are produced by 
ties.
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comparing HV to prostatitis patients. The bio-
chemical parameter usable for the distinction be-
tween HV and prostatitis patients were sPSA con-
centration, urinary WBC count and urinary bacte-
ria count; which were increased in prostatic in-
flammation. Next, we observed a lower amount of 
urinary tri- and tetraantennary N-glycans (3A/MA 
and 4A/MA marker, respectively) which resulted in 
an increase of biantennary structures (2A/MA 
marker). Combining urinary WBC count and the 
2A/MA marker proved favorable for prostatitis di-
agnosis compared to urinary WBC count as isolat-
ed test.
The most important parameter for the distinction 
between HV and prostatitis patients was urinary 
WBC count. Notable was that the reference criteri-
on (> 25 cells/µL) was higher than the post-hoc cal-
culated criterion (> 14.6 cells/µL). The same was 
noticed for the criterion value of urinary bacteria 
count (routinely used criterion > 11.4 bacteria/µL; 
calculated criterion > 6.5 bacteria/µL). This is prob-
able due to the bias that prostatitis patients were 
enrolled in the study until 6 weeks after onset of 
their symptoms and that some of them had al-
ready received antibiotic treatment. The urinary 
bacteria count proved also significantly to differ-
entiate prostatitis patients and HV. Again, this re-
sult is hard to interpret due to the design of our 
study and the fact that some of the prostatitis pa-
tients already received antibiotic treatment.
Next, the use of sPSA as a marker for prostatitis is 
contradictory as an elevated sPSA concentration 
can be the result of underlying subclinical disease 
such as BPH or PCa (6). Furthermore, Pansadoro et 
al . (19) found that in 72 prostatitis patients under 
50 year of age only 71% of patients with acute bac-
terial prostatitis, 15% of patients with chronic bac-
terial prostatitis and 6% of patients with chronic 
non-bacterial prostatitis had an elevated sPSA 
concentration (> 4 µg/L) because of increased vas-
cular permeability and disrupted prostate gland 
epithelium. Nadler et al. (20) even stated that sPSA, 
although slightly increased in patients with chron-
ic non-bacterial prostatitis (mean sPSA concentra-
tion = 1.97 µg/L, standard deviation = 2.87 µg/L), is 
not usable as biomarker for prostatitis due to the 
low sensitivity and specificity. Another study that 
evaluated the diagnostic performance of sPSA in 
prostatitis reported a decrease of the ratio free 
sPSA / total sPSA in acute bacterial prostatitis. We 
were unable to observe this difference for urinary 
PSA concentrations indicating that no error occurs 
in PSA synthesis in the prostate gland during in-
flammation of the prostate gland (21).
In contrast, we noticed that urinary albumin con-
centration was higher in prostatitis patients com-
pared to HV. This could be the consequence of 
leakage through the prostate gland. However, this 
parameter is of no significance for the differentia-
tion of prostatitis patients as it was within normal 
reference parameters (0-20 mg/L) (22).
Furthermore, we investigated the clinical utility of 
urinary N-glycosylation analysis in prostatitis diag-
nosis. As a post-translational modification, N-gly-
cosylation is highly sensitive to its environment 
and can be affected by disease status (23). The uri-
nary 2A/MA marker enabled distinction between 
prostatitis patients and HV, with similar diagnostic 
accuracy to urinary WBC and bacteria count. Com-
bining this urinary 2A/MA marker with urinary 
WBC count even improved the diagnostic perfor-
mance for prostatitis detection compared to uri-
nary WBC as isolated test.
The proposed combination of markers could show 
high potential for use in prostatitis diagnosis with 
some great advantages. Firstly, a model for prosta-
titis detection combining urinary WBC count and 
the urinary 2A/MA marker improved diagnostic 
accuracy by 9% which would greatly decrease the 
number of false-negatives derived by urinary WBC 
count and facilitate the difficult diagnosis of pros-
tatitis patients.
Secondly, our test uses a non-invasive method to 
obtain the urine samples. As the combination of 
urinary WBC count and the urinary 2A/MA marker 
achieved a fair diagnostic accuracy, this could pos-
sible decrease the need for invasive serum sam-
pling to determine other inflammatory markers, 
e.g. C-reactive protein.
Thirdly, as this technique is easy to use without pri-
or need for extensive training, easily repeatable, 
and affordable, implementation of this test in 
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centers with high number of urological specimens 
could be advisable.
An important remark is that HV are not age-
matched with the patient groups. As reported in 
previous publications (11,12), this was done delib-
erate to exclude presence of subclinical BPH or 
PCa in the HV group. However, this study design 
did not render the results less powerful because 
no differences were observed in N-glycosylation 
profiling when HV were subdivided into 3 age-in-
creasing categories (12). 
Surprisingly, we were unable to notice a difference 
between the N-glycosylation profile of acute bac-
terial prostatitis, chronic bacterial prostatitis and 
chronic non-bacterial prostatitis, nor when prosta-
titis patients were subdivided into acute versus 
chronic prostatitis patients or into bacterial versus 
non-bacterial prostatitis patients. This is probable 
due to the design of our study and as a direct ef-
fect thereof, the low number of patients in the 
prostatitis cohort.
Finally, an interesting finding is that no difference 
in overall core-α-1,6-fucosylation was found be-
tween HV and prostatitis patients, while previous-
ly this glycosylation change proved significant in 
the differentiation between HV, patients with BPH 
and PCa patients (12). However both prostatitis 
and BPH, which is characterized as an immune-
mediated inflammatory disease with characteris-
tics of chronic inflammation and significantly more 
infiltrated T-lymphocytes, macrophages and B-
lymphocytes (24-27), showed a decrease in triant-
ennary structures. This finding would indicate that 
the change in total amount of tri- and tetraanten-
nary structures / multiantennary structures could 
be associated with an inflammatory responses 
while the change in overall core-α-1,6-fucosylation 
is more likely an indicator of cancer progression. 
Both changes could possibly be linked as it has 
been stated that an inflammatory environment 
can be mutagenic and promote cancer progres-
sion, although there is still no evidence of a causal 
relation between inflammation and PCa (24,28-
30). 
In summary, we have demonstrated the diagnostic 
value of N-glycosylation profiling from urinary 
prostate proteins, as a possible biomarker for dif-
ferentiating HV from prostatitis patients. Further 
research is however warranted. An increased num-
ber of prostatitis patients could allow validating 
differences in N-glycan profiles between acute 
bacterial prostatitis, chronic bacterial prostatitis, 
chronic pelvic pain syndrome and asymptomatic 
prostatic inflammation which would have a great 
benefit for prostatitis diagnosis. Furthermore, 
comparison of N-glycosylation at time of disease 
onset and post treatment could help unravel the 
developmental course of prostatic inflammation 
indicate which patients are sensitive to chronifica-
tion of prostatitis. Lastly, comparison between 
prostatitis, BPH and PCa is needed as it could fur-
ther indicate the possible role of inflammation in 
the development of PCa.
Acknowledgements
This research was supported by the Clinical Re-
search Fund from the Ghent University Hospital.
Potential conflict of interest
None declared.
References
 1 . Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley 
DE . Epidemiology of prostatitis . Int J Antimicrob Agents 
2008;31S1:S85-90 . 
 2 . Krieger JN, Nyberg L Jr, Nickel JC . NIH consensus definiti-
on and classification of prostatitis . JAMA 1999;282:236-7 . 
http://dx .doi .org/10 .1001/jama .282 .3 .236 .
 3 . Grabe M, Bartoletti R, Bjerklund-Johansen TE, Çek HM, Pic-
kard RS, TenkeP, et al . Guidelines on Urological Infections 
2014 . Available at: http://www .uroweb .org/gls/pdf/19%20
Urological%20infections_LR .pdf . Accessed November 19 
2014 .
http://dx .doi .org/10 .11613/BM .2015 .045 Biochemia Medica 2015;25(3):439–49 
  449
Vermassen T. et al. Prostate protein glycosylation in prostatitis 
 4 . Ludwig M . Diagnosis and therapy of acute prostatitis, epi-
didymitis and orchitis . Andrologia 2008;40:76-80 . http://
dx .doi .org/10 .1111/j .1439-0272 .2007 .00823 .x .
 5 . Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, 
Altmannsberger M . Chronic prostatitis: a thorough search 
for etiologically involved microorganisms in 1,461 patients . 
Infection 1991;19S3:S119-125 .
 6 . Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, 
Han M, et al . Prostate specific antigen best practice state-
ment: 2009 update . J Urol 2013;189S1:S2-S11 .
 7 . Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden 
DL, Bennett CL, et al . IL-1beta and TNF-alpha in prosta-
tic secretions are indicators in the evaluation of men with 
chronic prostatitis . J Urol 2000;164:214-8 . http://dx .doi .
org/10 .1016/S0022-5347(05)67497-6 .
 8 . Everaert K, Delanghe J, Vanderkelen M, Cornelis K, De 
Wachter S, Viaene A, et al . Urinary plasma protein patterns 
in acute prostatitis . Clin Chem Lab Med 2003;41:79-84 . 
http://dx .doi .org/10 .1515/cclm .2003 .014 .
 9 . Penders J, Fiers T, Everaert K, Barth J, Dhondt AW, Delanghe 
JR . Diagnostic performance of combined specific urinary 
proteins and urinary flow cytometry in urinary tract pat-
hology . Clin Chem Lab Med 2007;45:499-504 . http://dx .doi .
org/10 .1515/cclm .2007 .090 .
10 . Kreisman LS, Cobb BA . Infection, inflammation and host 
carbohydrates: a Glyco-Evasion Hypothesis . Glycobio-
logy 2012;22:1019-30 . http://dx .doi .org/10 .1093/glycob/
cws070 .
11 . Vermassen T, Van Praet C, Vanderschaeghe D, Maenhout 
T, Lumen N, Callewaert N, et al . Capillary electrophoresis 
of urinary prostate glycoproteins assists in the diagnosis of 
prostate cancer . Electrophoresis 2014;35:1017-24 . http://
dx .doi .org/10 .1002/elps .201300332 .
12 . Vermassen T, Van Praet C, Lumen N, Decaestecker K, Van-
derschaeghe D, Callewaert N, et al . Urinary prostate pro-
tein glycosylation profiling as a diagnostic biomarker for 
prostate cancer . Prostate 2015;75:314-22 . http://dx .doi .
org/10 .1002/pros .22918 .
13 . Orsonneau JL, Douet P, Massoubre C, Lustenberger P, Ber-
nard S . An improved pyrogallol red-molybdate method for 
determining total urinary protein . Clin Chem 1989;35:2233-
6 .
14 . Blasco V, Wiramus S, Textoris J, Antonini F, Bechis C, 
Albanèse J, Martin C, Leone M . Monitoring of plasma cre-
atinine and urinary γ-glutamyltranspeptidase impro-
ves detection of acute kidney injury by more than 20% . 
Crit Care Med 2011;39:52-6 . http://dx .doi .org/10 .1097/
CCM .0b013e3181fa431a .
15 . Lisowska-Myjak B . Serum and Urinary Biomarkers of Acu-
te Kidney Injury . Blood Purif 2010;29:357-65 . http://dx .doi .
org/10 .1159/000309421 .
16 . Szasz G, Persijn JP, Coll E . Kinetic Method for quantitative 
determination of gammaglutamyltranspeptidase . Z Klin 
Chem Klin Biochem 1974;12:228 .
17 . Wang J, Zhang Y, Xu D, Shao W, Lu Y . Evaluation of the 
Sysmex UF-1000i for the diagnosis of urinary tract in-
fection . Am J Clin Pathol 2010;133:577-82 . http://dx .doi .
org/10 .1309/ajcp1gt2jxocqbcz .
18 . Manoni F, Tinello A, Fornasiero L, Hoffer P, Temporin V, Val-
verde S, Gessoni G . Urine particle evaluation: a compa-
rison between the UF-1000i and quantitative microsco-
py . Clin Chem Lab Med 2010;48:1107-11 . http://dx .doi .
org/10 .1515/cclm .2010 .233 .
19 . Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, 
Brisciani A, Lauretti S . Prostate-specific antigen and prosta-
titis in men under fifty . Eur Urol 1996;30:24-7 .
20 . Nadler RB, Collins MM, Propert KJ, Mikolajczyk SD, Kna-
uss JS, Landis JR, et al . Prostate specific antigen test in di-
agnostic evaluation of chronicprostatitis/chronic pel-
vic pain syndrome . Urology 2006;67:337-42 . http://dx .doi .
org/10 .1016/j .urology .2005 .08 .031 .
21 . Gamé X, Vincendeau S, Palascak R, Milcent S, Fournier R, 
Houlgatte A . Total and free serum prostate specific anti-
gen levels during the first month of acute prostatitis . Eur 
Urol 2003;43:702-5 . http://dx .doi .org/10 .1016/S0302-
2838(03)00158-1 .
22 . Thomas L . Clinical laboratory diagnostics: Use and asse-
ssment of clinical laboratory results . 1st ed . Washington, 
DC, USA: American Association for Clinical Chemistry, 
1998 .
23 . Ohtsubo K, Marth JD . Glycosylation in cellular mechanisms 
of health and disease . Cell 2006;126:855-67 . http://dx .doi .
org/10 .1016/j .cell .2006 .08 .019 .
24 . Kramer G, Mitteregger D, Marberger M . Is benign prosta-
tic hyperplasia (BPH) an immune inflammatory disease? 
Eur Urol 2007;51:1202-16 . http://dx .doi .org/10 .1016/j .euru-
ro .2006 .12 .011 .
25 . Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, 
Marberger M, et al . Phenotypic characterization of infiltra-
ting leukocytes in benign prostatic hyperplasia . Lab Invest 
1992;66:96-107 .
26 . Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer 
B, et al . Increased expression of lymphocyte-derived cyto-
kines in benign hyperplastic prostate tissue, identificati-
on of the producing cell types, and effect of differentially 
expressed cytokines on stromal cell proliferation . Prostate 
2002;52:43-58 . http://dx .doi .org/10 .1002/pros .10084 .
27 . Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, 
Reithmayr F, et al . Cytokine expression pattern in beni-
gn prostatic hyperplasia infiltrating T cells and impact of 
lymphocytic infiltration on cytokine mRNA profile in pro-
static tissue . Lab Invest 2003;83:1131-46 . http://dx .doi .
org/10 .1097/01 .LAB .0000081388 .40145 .65 .
28 . Nickel JC, Downey J, Young I, Boag S . Asymptomatic in-
flammation and/or infection in benign prostatic hyper-
plasia . BJU Int 1999;84:976-81 . http://dx .doi .org/10 .1046/
j .1464-410x .1999 .00352 .x .
29 . Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gen-
tilucci A, Gentile V . Inflammation and chronic prostatic di-
seases: evidence for a link? Eur Urol 2007;52:964-72 . http://
dx .doi .org/10 .1016/j .eururo .2007 .06 .038 .
30 . De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson 
W, Schröder F, et al . The controversial relationship between 
benign prostatic hyperplasia and prostate cancer: the role 
of inflammation . Eur Urol 2011;60:106-17 . http://dx .doi .
org/10 .1016/j .eururo .2011 .03 .055 .
